Literature DB >> 4712483

Cyclophosphamide in treatment of systemic lupus erythematosus: 7 years' experience.

P H Feng, F J Jayaratnam, E P Tock, C S Seah.   

Abstract

This paper describes our experience with cyclophosphamide in the treatment of systemic lupus erythematosus. Since 1965 42 such patients have been treated either singly with cyclophosphamide or in combination with steroid. Serious complications have been rare except for amenorrhoea, which occurred in 14 out of 32 patients within the reproductive period. Our experience suggests that cyclophosphamide has an important, though not primary, part to play in the therapy of this disease.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4712483      PMCID: PMC1589465          DOI: 10.1136/bmj.2.5864.450

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  10 in total

1.  THE NATURAL HISTORY OF THE RENAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS.

Authors:  V E POLLAK; C L PIRANI; F D SCHWARTZ
Journal:  J Lab Clin Med       Date:  1964-04

2.  Lupus nephritis. Clinical and histologic survey.

Authors:  R M WILSON; J F MAHER; G E SCHREINER
Journal:  Arch Intern Med       Date:  1963-04

3.  Corticotropin and cortisone in acute disseminated lupus erythematosus; results of long-term use.

Authors:  L J SOFFER; R BADER
Journal:  J Am Med Assoc       Date:  1952-07-12

4.  Cyclophosphamide treatment of renal disease in (NZB x NZW) F1 hybrid mice.

Authors:  P J Russell; J D Hicks
Journal:  Lancet       Date:  1968-03-02       Impact factor: 79.321

5.  Cyclophosphamide and infertility.

Authors:  P H Feng; C R George; R A Evans; G E Murkin; E Spicer; B S Thomas; K Hellmann; H Hassib; F Hassib
Journal:  Lancet       Date:  1972-04-15       Impact factor: 79.321

6.  The prognosis of lupus nephritis. Role of clinical-pathologic correlations.

Authors:  B Zweiman; J Kornblum; J Cornog; E A Hildreth
Journal:  Ann Intern Med       Date:  1968-09       Impact factor: 25.391

7.  Multiple late complications of therapy with cyclophosphamide, including ovarian destruction.

Authors:  J J Miller; G F Williams; J C Leissring
Journal:  Am J Med       Date:  1971-04       Impact factor: 4.965

8.  Cyclophosphamide in systemic lupus erythematosus.

Authors:  T Hadidi
Journal:  Ann Rheum Dis       Date:  1970-11       Impact factor: 19.103

9.  Treatment of lupus nephritis with cyclophosphamide.

Authors:  J S Cameron; M Boulton-Jones; R Robinson; C Ogg
Journal:  Lancet       Date:  1970-10-24       Impact factor: 79.321

10.  Cyclophosphamide in the treatment of systemic lupus erythematosus.

Authors:  C Siang; K H Wong; A G Chew; F J Jayaratnam
Journal:  Br Med J       Date:  1966-02-05
  10 in total
  3 in total

Review 1.  Clinical trials in lupus nephritis.

Authors:  E M Ginzler
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 2.  Clinical use of immunosuppressive drugs: part I.

Authors:  N L Gerber; A D Steinberg
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 3.  Recent advances in the immunopathogenesis of systemic lupus erythematosus.

Authors:  E J Bardana; B Pirofsky
Journal:  West J Med       Date:  1975-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.